Literature DB >> 10677352

Reagent or myeloperoxidase-generated hypochlorite affects discrete regions in lipid-free and lipid-associated human apolipoprotein A-I.

C Bergt1, K Oettl, W Keller, F Andreae, H J Leis, E Malle, W Sattler.   

Abstract

We have previously shown that the modification of high-density lipoprotein subclass 3 (HDL(3)) by HOCl transformed an anti-atherogenic lipoprotein into a high-uptake form for macrophages and caused a significant impairment of cholesterol efflux capacity [Panzenboeck, Raitmayer, Reicher, Lindner, Glatter, Malle and Sattler (1997) J. Biol. Chem. 272, 29711-29720]. To elucidate the consequences of treatment with OCl(-) on distinct regions in apolipoprotein A-I (apo A-I), lipid-free and lipid-associated apo A-I were modified with increasing molar ratios of NaOCl or HOCl generated by the myeloperoxidase/H(2)O(2)/Cl(-) system. CD analysis revealed a pronounced decrease in alpha-helicity for lipid-free apo A-I modified by NaOCl, whereas lipid-associated apo A-I was less affected. The modification of apo A-I by NaOCl (molar oxidant-to-lipoprotein ratio 6:1) resulted in the formation of two distinct oxidized forms of apo A-I with molecular masses 32 or 48 atomic mass units (a.m.u.) higher than that of native apo A-I, indicating the addition of two or three oxygen atoms to the native protein. HPLC analysis of tryptic digests obtained from lipid-free and lipid-associated apo A-I modified with increasing oxidant-to-apolipoprotein molar ratios revealed a concentration-dependent modification of apo A-I: at a low molar oxidant-to-lipoprotein ratio (5:1) the peaks corresponding to the methionine-containing tryptic peptides T11 (residues 84-88), T16 (residues 108-116) and T22 (residues 141-149), located in the central region of apo A-I, disappeared. Their loss was accompanied by the formation of three oxidation products with a molecular mass 16 a.m.u. higher than that of the native peptides. This indicates the addition of oxygen, most probably caused by the oxidation of Met(86), Met(112) and Met(148) to the corresponding methionine sulphoxides. At a molar NaOCl-to-apo A-I ratio of 10:1 the disappearance of peptides T1 (residues 1-10), T7 (residues 46-59) and T9 (residues 62-77) was accompanied by the occurrence of new peaks 33.5 and 33.1 a.m.u. higher than those of the native peptides. Amino acid analyses of peptides T7 and T9 after modification with NaOCl confirmed that Phe(57) and Phe(71) were primary targets for oxidation by HOCl. GLC-MS analysis of hydrolysates obtained from OCl(-)-modified T7, T9, apo A-I and HDL(3) confirmed that Phe residues are an early target for OCl(-) modification. At molar NaOCl-to-apo A-I ratios of 25:1, the peak areas of peptides T31 (residues 189-195) and T32 (residues 196-206) decreased markedly. Most importantly, incubation of apo A-I with the myeloperoxidase/H(2)O(2)/Cl(-) system (the source of HOCl in vivo) resulted in almost identical modification patterns to those observed with reagent NaOCl.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10677352      PMCID: PMC1220859     

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  48 in total

Review 1.  Lecithin-cholesterol acyltransferase in the metabolism of high-density lipoproteins.

Authors:  A Jonas
Journal:  Biochim Biophys Acta       Date:  1991-07-30

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  High performance liquid chromatography and time-of-flight secondary ion mass spectrometry: a new dimension in structural analysis of apolipoproteins.

Authors:  H U Jabs; G Assmann; D Greifendorf; A Benninghoven
Journal:  J Lipid Res       Date:  1986-06       Impact factor: 5.922

4.  Calculation of protein conformation from circular dichroism.

Authors:  J T Yang; C S Wu; H M Martinez
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

5.  Reconstitution of high-density lipoproteins.

Authors:  A Jonas
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

6.  Properties of lipid . apolipoprotein association products. Complexes of dimyristoyl phosphatidylcholine and human apo A-1.

Authors:  J B Swaney
Journal:  J Biol Chem       Date:  1980-02-10       Impact factor: 5.157

7.  The oxidant hypochlorite (OCl-), a product of the myeloperoxidase system, degrades articular cartilage proteoglycan aggregate.

Authors:  M Katrantzis; M S Baker; C J Handley; D A Lowther
Journal:  Free Radic Biol Med       Date:  1991       Impact factor: 7.376

8.  Effect of oxidation on the properties of apolipoproteins A-I and A-II.

Authors:  G M Anantharamaiah; T A Hughes; M Iqbal; A Gawish; P J Neame; M F Medley; J P Segrest
Journal:  J Lipid Res       Date:  1988-03       Impact factor: 5.922

9.  Site-specific methionine sulfoxide formation is the structural basis of chromatographic heterogeneity of apolipoproteins A-I, C-II, and C-III.

Authors:  A von Eckardstein; M Walter; H Holz; A Benninghoven; G Assmann
Journal:  J Lipid Res       Date:  1991-09       Impact factor: 5.922

Review 10.  Mechanisms and consequences of cellular cholesterol exchange and transfer.

Authors:  M C Phillips; W J Johnson; G H Rothblat
Journal:  Biochim Biophys Acta       Date:  1987-06-24
View more
  17 in total

1.  Myeloperoxidase, inflammation, and dysfunctional high-density lipoprotein.

Authors:  Jonathan D Smith
Journal:  J Clin Lipidol       Date:  2010 Sep-Oct       Impact factor: 4.766

2.  Hypochlorite modification of sphingomyelin generates chlorinated lipid species that induce apoptosis and proteome alterations in dopaminergic PC12 neurons in vitro.

Authors:  Christoph Nusshold; Manfred Kollroser; Harald Köfeler; Gerald Rechberger; Helga Reicher; Andreas Ullen; Eva Bernhart; Sabine Waltl; Ingrid Kratzer; Albin Hermetter; Hubert Hackl; Zlatko Trajanoski; Andelko Hrzenjak; Ernst Malle; Wolfgang Sattler
Journal:  Free Radic Biol Med       Date:  2010-03-11       Impact factor: 7.376

3.  The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport.

Authors:  Constanze Bergt; Subramaniam Pennathur; Xiaoyun Fu; Jaeman Byun; Kevin O'Brien; Thomas O McDonald; Pragya Singh; G M Anantharamaiah; Alan Chait; John Brunzell; Randolph L Geary; John F Oram; Jay W Heinecke
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

4.  Hypochlorite-modified high-density lipoprotein acts as a sink for myeloperoxidase in vitro.

Authors:  Gunther Marsche; Paul G Furtmüller; Christian Obinger; Wolfgang Sattler; Ernst Malle
Journal:  Cardiovasc Res       Date:  2008-02-23       Impact factor: 10.787

5.  Characterization of non-covalent oligomers of proteins treated with hypochlorous acid.

Authors:  Anna L P Chapman; Christine C Winterbourn; Stephen O Brennan; T William Jordan; Anthony J Kettle
Journal:  Biochem J       Date:  2003-10-01       Impact factor: 3.857

Review 6.  Dysfunctional HDL as a diagnostic and therapeutic target.

Authors:  Jonathan D Smith
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-08-13       Impact factor: 8.311

7.  Mild oxidation promotes and advanced oxidation impairs remodeling of human high-density lipoprotein in vitro.

Authors:  Xuan Gao; Shobini Jayaraman; Olga Gursky
Journal:  J Mol Biol       Date:  2007-12-23       Impact factor: 5.469

Review 8.  Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein.

Authors:  Baohai Shao; Michael N Oda; John F Oram; Jay W Heinecke
Journal:  Chem Res Toxicol       Date:  2010-03-15       Impact factor: 3.739

9.  Effects of protein oxidation on the structure and stability of model discoidal high-density lipoproteins.

Authors:  Shobini Jayaraman; Donald L Gantz; Olga Gursky
Journal:  Biochemistry       Date:  2008-02-27       Impact factor: 3.162

10.  In vivo administration of BL-3050: highly stable engineered PON1-HDL complexes.

Authors:  Leonid Gaidukov; Dganit Bar; Shiri Yacobson; Esmira Naftali; Olga Kaufman; Rinat Tabakman; Dan S Tawfik; Etgar Levy-Nissenbaum
Journal:  BMC Clin Pharmacol       Date:  2009-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.